CSF3 and liver disorder: Transplant free survival at 12 months was significantly improved in both groups of G-CSF-treated patients, associated with decreased measures of liver disease severity and a significant reduction in the odds of developing a bacterial infection (including ~88% reduction in the odds of developing sepsis).